Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
2001 Standout
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Infective Endocarditis
2005 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
1993
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
Testicular Germ-Cell Cancer
1997 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
A view on drug resistance in cancer
2019 StandoutNature
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
1988
Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy A prospective trial
1992
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
1990
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
2002
Focus on bladder cancer
2004
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Cushing's syndrome
2015 Standout
Head and neck cancer
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Renal-Cell Carcinoma
1996 Standout
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
2003 Standout
INDICATIONS FOR PELVIC LYMPHADENECTOMY IN PROSTATE CANCER
2001
Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer.
1989
Mechanisms of Action and Clinical Uses of Estramustine
1990
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
2013
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
1998
Gemcitabine in transitional cell carcinoma of the urothelium
2003
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells
1989 StandoutNature
The State of the Art in Radiation Therapy
2006
Bladder cancer: Long-term follow-up results of patients treated with radical radiation
1991
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
2006
Management of Hepatocellular Carcinoma *
2005 Standout
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
2006
Clinical and Surgical Staging of Non-Small Cell Lung Cancer
2000
Phase II study ofcis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract
1992
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Bladder cancer
2016 Standout
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
1992
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
2005
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
1991 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group.
1996
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
1997
Prevention of Venous Thromboembolism
2004 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer
2005
Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction
1992 Standout
The role of antisense oligonucleotides in the treatment of bladder cancer
2002
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2003 Standout
Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
1990
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
2001
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
1989
Retroviral vectors displaying functional antibody fragments
1993 StandoutNobel
Role of gemcitabine in cancer therapy
2005
Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer
2000
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
1999
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Liposomal cisplatin: a new cisplatin formulation
2010
Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
1995
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.
1990
Deep Venous Thrombosis
1991
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer
1991
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
1994
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC
2001
METASTATIC BLADDER CANCER
1992
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma
2000
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
1985
Nanoscale Metal–Organic Frameworks for Biomedical Imaging and Drug Delivery
2011 Standout
Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases
1971
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
2000
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
2009
Retroviral-mediated gene transfer into hepatocytes in vivo.
1991
Plasmacytoid Carcinoma of the Bladder: A Urothelial Carcinoma Variant With a Predilection for Intraperitoneal Spread
2012
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
2004
Bladder Cancer
2020 Standout
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
2005
Papillary renal cell carcinoma.A clinical, radiologic, and pathologic study of 34 cases
1976
The Rationale for EN Bloc Pelvic Lymph Node Dissection for Bladder Cancer Patients with Nodal Metastases: Long-Term Results
1993
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
1985
Evolution of the Management of Stage I Nonseminomatous Germ-cell Tumors of the Testis
1991
Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group
1999
Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy
1996
Complications of indwelling chemotherapy catheters
1975
Is Heparin Contraindicated in Pelvic Lymphadenectomy and Radical Prostatectomy?
1997
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
1998
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
2014
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma
1998
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
2001
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
1994 StandoutNobel
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
2000
Cancer of the Pancreas
1979
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
1999
The Role of Adjuvant Chemotherapy Following Cystectomy for Invasive Bladder Cancer: A Prospective Comparative Trial
1991
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
2005 Standout
Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
2014
Splenic Abscess Complicating Infectious Endocarditis
1983
Radical Cystectomy for Carcinoma of the Bladder: Critical Evaluation of the Results in 1,026 Cases
1997
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Cisplatin
1984 Standout
Works of Robin C. Watson being referenced
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
1989
Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
1985
Methotrexate: An active drug in bladder cancer
1981
A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II
1979
Arteriography in the Diagnosis of Renal Carcinoma
1968
Radiation treatment planning
1977
Phase II Trial of Doxorubicin in Bidimensionally Measurable Prostatic Adenocarcinoma
1984
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.
1984
Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer
1978
The value of diagnostic aids in detecting pancreas cancer
1978
Major Hepatic Resection Using Vascular Isolation and Hypothermic Perfusion
1974
Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.
1985
Treatment of Primary and Secondary Liver Cancer by Hepatic Artery Ligation and Infusion Chemotherapy
1973
Cisplatin for adrenal cortical carcinoma.
1983
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease
1986
The Angiographic Appearance of Splenic Masses
1972
Phase II trial of 4ʼepi-adriamycin for advanced hypernephroma
1983
Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature
1977
Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors
1982
Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer. Toxicity of a five-day IV bolus schedule
1980
Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma
1985
M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium
1988
Surgery in liver tumors
1972
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide
1984
Lymphocele after pelvic lymphadenectomy for urologic cancer
1981
Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion
1988
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma
1985
Phase II trial of 4ʼepi-adriamycin for advanced hypernephroma
1983